Mesoblast (MESO) Competitors

Mesoblast logo
$12.45 -0.82 (-6.18%)
Closing price 04:00 PM Eastern
Extended Trading
$12.43 -0.02 (-0.16%)
As of 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MESO vs. ORKA, ARWR, CYTK, KOD, and CGON

Should you buy Mesoblast stock or one of its competitors? Mesoblast's main competitors and comparable companies include Oruka Therapeutics (ORKA), Arrowhead Pharmaceuticals (ARWR), Cytokinetics (CYTK), Kodiak Sciences (KOD), and CG Oncology (CGON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Mesoblast compare to Oruka Therapeutics?

Mesoblast (NASDAQ:MESO) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Mesoblast has higher revenue and earnings than Oruka Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$120.25M14.36-$57.50MN/AN/A
Oruka TherapeuticsN/AN/A-$105.43M-$2.11N/A

Mesoblast presently has a consensus price target of $39.00, indicating a potential upside of 193.90%. Oruka Therapeutics has a consensus price target of $141.80, indicating a potential upside of 34.60%. Given Mesoblast's higher probable upside, equities analysts clearly believe Mesoblast is more favorable than Oruka Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mesoblast
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Oruka Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

In the previous week, Oruka Therapeutics had 15 more articles in the media than Mesoblast. MarketBeat recorded 28 mentions for Oruka Therapeutics and 13 mentions for Mesoblast. Oruka Therapeutics' average media sentiment score of 0.02 beat Mesoblast's score of 0.00 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mesoblast
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral
Oruka Therapeutics
7 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Mesoblast's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MesoblastN/A N/A N/A
Oruka Therapeutics N/A -19.34%-18.74%

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Mesoblast has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, indicating that its share price is 134% less volatile than the broader market.

Summary

Mesoblast and Oruka Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Mesoblast compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Mesoblast (NASDAQ:MESO) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Mesoblast has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -160.64%. Mesoblast's return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Arrowhead Pharmaceuticals-160.64% -172.62% -37.51%
Mesoblast N/A N/A N/A

Mesoblast has lower revenue, but higher earnings than Arrowhead Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$450.82M14.93-$724.21M-$2.25N/A
Mesoblast$120.25M14.36-$57.50MN/AN/A

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Mesoblast. MarketBeat recorded 21 mentions for Arrowhead Pharmaceuticals and 13 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.00 beat Arrowhead Pharmaceuticals' score of -0.02 indicating that Mesoblast is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arrowhead Pharmaceuticals
3 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Mesoblast
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral

Arrowhead Pharmaceuticals presently has a consensus target price of $98.93, indicating a potential upside of 107.05%. Mesoblast has a consensus target price of $39.00, indicating a potential upside of 193.90%. Given Mesoblast's higher probable upside, analysts plainly believe Mesoblast is more favorable than Arrowhead Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arrowhead Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.73
Mesoblast
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Mesoblast beats Arrowhead Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Mesoblast compare to Cytokinetics?

Mesoblast (NASDAQ:MESO) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Mesoblast has higher revenue and earnings than Cytokinetics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$120.25M14.36-$57.50MN/AN/A
Cytokinetics$113.29M69.02-$784.96M-$6.04N/A

Mesoblast has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

In the previous week, Mesoblast had 1 more articles in the media than Cytokinetics. MarketBeat recorded 13 mentions for Mesoblast and 12 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.81 beat Mesoblast's score of 0.00 indicating that Cytokinetics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mesoblast
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral
Cytokinetics
5 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Mesoblast presently has a consensus target price of $39.00, suggesting a potential upside of 193.90%. Cytokinetics has a consensus target price of $106.67, suggesting a potential upside of 90.04%. Given Mesoblast's higher probable upside, research analysts clearly believe Mesoblast is more favorable than Cytokinetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mesoblast
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Cytokinetics
1 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86

1.4% of Mesoblast shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Mesoblast has a net margin of 0.00% compared to Cytokinetics' net margin of -686.63%.

Company Net Margins Return on Equity Return on Assets
MesoblastN/A N/A N/A
Cytokinetics -686.63%N/A -48.26%

Summary

Mesoblast beats Cytokinetics on 9 of the 13 factors compared between the two stocks.

How does Mesoblast compare to Kodiak Sciences?

Mesoblast (NASDAQ:MESO) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

In the previous week, Mesoblast and Mesoblast both had 13 articles in the media. Kodiak Sciences' average media sentiment score of 0.54 beat Mesoblast's score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mesoblast
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral
Kodiak Sciences
1 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Mesoblast presently has a consensus price target of $39.00, suggesting a potential upside of 193.90%. Kodiak Sciences has a consensus price target of $109.00, suggesting a potential downside of 1.97%. Given Mesoblast's higher possible upside, analysts plainly believe Mesoblast is more favorable than Kodiak Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mesoblast
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

Mesoblast has higher revenue and earnings than Kodiak Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$120.25M14.36-$57.50MN/AN/A
Kodiak SciencesN/AN/A-$229.97M-$4.08N/A

Mesoblast's return on equity of 0.00% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
MesoblastN/A N/A N/A
Kodiak Sciences N/A -287.64%-87.83%

Mesoblast has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market.

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Mesoblast beats Kodiak Sciences on 6 of the 11 factors compared between the two stocks.

How does Mesoblast compare to CG Oncology?

Mesoblast (NASDAQ:MESO) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Mesoblast currently has a consensus price target of $39.00, indicating a potential upside of 193.90%. CG Oncology has a consensus price target of $88.11, indicating a potential upside of 18.43%. Given Mesoblast's higher possible upside, equities research analysts clearly believe Mesoblast is more favorable than CG Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mesoblast
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
CG Oncology
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73

In the previous week, CG Oncology had 7 more articles in the media than Mesoblast. MarketBeat recorded 20 mentions for CG Oncology and 13 mentions for Mesoblast. CG Oncology's average media sentiment score of 0.57 beat Mesoblast's score of 0.00 indicating that CG Oncology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mesoblast
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral
CG Oncology
4 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Mesoblast has higher revenue and earnings than CG Oncology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$120.25M14.36-$57.50MN/AN/A
CG Oncology$4.04M1,644.90-$160.99M-$2.76N/A

Mesoblast has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Mesoblast has a net margin of 0.00% compared to CG Oncology's net margin of -3,851.09%. Mesoblast's return on equity of 0.00% beat CG Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
MesoblastN/A N/A N/A
CG Oncology -3,851.09%-24.58%-23.40%

Summary

Mesoblast beats CG Oncology on 8 of the 14 factors compared between the two stocks.

Get Mesoblast News Delivered to You Automatically

Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MESO vs. The Competition

MetricMesoblastBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.70B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E RatioN/A26.5532.9127.39
Price / Sales13.4716.028.595.74
Price / CashN/A26.3721.9322.50
Price / Book2.844.074.403.70
Net Income-$57.50M-$22.86M$3.52B$392.17M
7 Day Performance-13.78%-7.26%-5.34%-4.53%
1 Month Performance-6.25%-4.96%-3.61%-5.86%
1 Year Performance-15.71%-2.87%0.01%-7.78%

Mesoblast Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MESO
Mesoblast
1.8404 of 5 stars
$12.45
-6.2%
$39.00
+213.3%
-10.2%$1.70B$120.25MN/A108
ORKA
Oruka Therapeutics
2.5702 of 5 stars
$105.03
+0.4%
$133.00
+26.6%
+289.0%$6.95BN/AN/A68
ARWR
Arrowhead Pharmaceuticals
2.9457 of 5 stars
$48.55
-1.4%
$99.07
+104.1%
+15.8%$6.84B$829.45MN/A711
CYTK
Cytokinetics
3.066 of 5 stars
$54.67
-0.9%
$106.67
+95.1%
-15.5%$6.81B$88.04MN/A673
KOD
Kodiak Sciences
2.3576 of 5 stars
$105.86
-1.2%
$104.71
-1.1%
+469.9%$6.66BN/AN/A124

Related Companies and Tools


This page (NASDAQ:MESO) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners